Everforth Inc quarterly report, Q2 FY2011

On Assignment, Inc. — Form 10-Q Summary

Issuer identification: The filing cover identifies the registrant as On Assignment, Inc.; the request metadata names Everforth Inc. This summary reflects the filing itself.

Business context and reporting period

The filing reports the quarter and six months ended June 30, 2011, compared with the corresponding 2010 periods. On Assignment provided specialty staffing in Life Sciences, Healthcare, Physician, and IT and Engineering. Results are unaudited. Management cautions that interim results are not necessarily indicative of full-year results.

Key financial metrics

MetricQ2 2011Q2 2010Six months 2011Six months 2010
Revenue$143.7 million$104.5 million$273.1 million$200.8 million
Gross profit / margin$48.8 million / 34.0%$35.3 million / 33.8%$91.9 million / 33.7%$66.1 million / 32.9%
Operating income / margin$10.8 million / 7.5%$3.3 million / 3.2%$17.2 million / 6.3%$4.3 million / 2.1%
Net income$5.9 million$0.9 million$9.0 million$0.6 million
Diluted EPS$0.16$0.03$0.24$0.02
  • Q2 revenue rose 37.5% year over year; six-month revenue rose 36.0%. Q2 net income increased to $5.9 million from $0.9 million.
  • Six-month operating cash flow was $12.9 million, versus $14.5 million. Investing cash flow was negative $21.5 million, including $17.1 million of acquisition payments and $4.7 million of capital expenditures. Financing cash flow was positive $9.1 million.
  • Cash was $19.2 million at June 30, 2011, versus $18.4 million at year-end 2010; reported working capital was $54.5 million.
  • Total debt was $77.3 million, up from $66.8 million at year-end: $31.0 million drawn on the revolving facility and $46.3 million on the term loan. The company reported compliance with its financial covenants.
  • Accounts receivable increased to $80.8 million from $62.5 million at year-end. Goodwill was $216.4 million; total assets were $383.7 million.

Material changes versus the prior comparable period

  • Revenue growth was led by IT and Engineering, up 58.4% in Q2, and Life Sciences, up 55.3%. Healthcare revenue rose 12.6%; Physician revenue declined 7.7%.
  • Higher revenue and a favorable mix, together with Life Sciences margin expansion, lifted consolidated Q2 gross margin by 20 basis points. SG&A increased 18.9% in Q2, slower than revenue growth, and fell to 26.5% of revenue from 30.6%.
  • Six-month interest expense declined to $1.5 million from $3.2 million, which management attributed to lower average interest rates and debt balances.
  • Foreign revenue increased to $32.8 million for the six months from $12.8 million, with acquisitions and business growth contributing to the change.

Outlook, commentary, risks, and unusual items

  • Management said demand strengthened across the segments and that revenue and EPS grew year over year and sequentially. It gave no specific numerical earnings or revenue guidance, but said working capital, the credit facility, and expected operating cash flows should fund requirements for the next 12 months.
  • Management expects to pursue both organic growth and strategic acquisitions. It estimated 2011 capital expenditures at approximately $8.1 million. Staffing demand is typically stronger in the second and third quarters and weaker in the first and fourth quarters.
  • Valesta, a European clinical research staffing provider, was acquired in February for an estimated $23.6 million, including $16.8 million paid at closing and contingent consideration. Its post-acquisition results contributed $8.5 million in revenue and $0.2 million in net income through June 30. Purchase accounting remained preliminary.
  • On July 31, 2011, after quarter-end, the company completed its acquisition of HealthCare Partners for $15.0 million cash, paid August 1, with a further $3.7 million earn-out opportunity. Acquisition accounting and pro forma information were incomplete.
  • Q2 SG&A included a $1.3 million gain from settlement of the Cambridge acquisition earn-out. Q1 SG&A included approximately $0.4 million of Valesta transaction costs. Acquisition-related activity also increased goodwill and contingent consideration.
  • Risks cited include economic uncertainty, demand for staffing services, recruiting and retaining qualified professionals, competition, growth management, information-system performance, healthcare-reform uncertainty, foreign currency, and variable interest rates. A $25 million interest-rate swap hedged part of the debt exposure; the filing estimated that a 1% rate change would alter annual interest expense by approximately $0.5 million after the swap.
  • The company reported ordinary-course legal matters that it did not expect to have a material adverse effect, and said there were no material changes to previously disclosed risk factors. Disclosure controls were assessed as effective.

Important facts for investors to verify

  • How much of revenue and earnings growth came from acquired businesses versus organic demand, particularly in Life Sciences and IT and Engineering.
  • Whether higher accounts receivable and working-capital needs convert into sustained operating cash flow.
  • The final Valesta purchase-price allocation and earn-out exposure, and the subsequent financial contribution and accounting for HealthCare Partners.
  • Whether the Physician segment’s revenue decline and Healthcare segment’s still-soft demand improve, and the effect of healthcare-reform uncertainty.
  • Debt levels, covenant headroom, variable-rate exposure, and the company’s ability to meet scheduled repayments while funding acquisitions and capital expenditures.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.